Following the scientific advice meeting with The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, Geneva-based Adiposs received an endorsement for its flagship product, ImageBAT, to proceed to clinical trials.
Geneva University spin-off Adiposs founded by Andrej Babic and Justyna Plewka is developping ImageBAT, the first product that makes brown and beige adipose tissue (BAT) visible with a fast and pain-free CT (computed tomography) scan. It enables early detection of cachexia before patients lose body weight. Cancer cachexia is a severe body-wasting syndrome characterised by involuntary body weight loss. It affects more than half of all cancer patients and is the cause of death in a fifth of all cancer patients.
Following the endorsement of the The MHRA in the UK, Phase I Clinical Trial is planned to start in the second half of 2021 and is meant to explore the safety, tolerability and pharmacokinetics of ImageBAT and to establish the effective dose for ImageBAT-enhanced CT imaging of brown adipose tissue.
“ImageBAT has the potential to improve quality of life and outcomes in patients with cancer and chronic diseases. I am proud of the Adiposs team which has advanced it up to human clinical trials” said Dr. Andrej Babic, CEO of Adiposs.
Please login or sign up to comment.
Commenting guidelines